Zicronapine

Atypical antipsychotic medication
Zicronapine
Identifiers
  • 4-[(1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine
CAS Number
  • 170381-16-5
PubChem CID
  • 11465618
DrugBank
  • DB05828
ChemSpider
  • 9640456
UNII
  • QZV11V7G6A
KEGG
  • D10329 checkY
CompTox Dashboard (EPA)
  • DTXSID30168849 Edit this at Wikidata
Chemical and physical data
FormulaC22H27ClN2
Molar mass354.92 g·mol−1
3D model (JSmol)
  • Interactive image
  • Clc1ccc4c(c1)[C@H](N2CC(N(C)CC2)(C)C)C[C@H]4c3ccccc3
InChI
  • InChI=1S/C22H27ClN2/c1-22(2)15-25(12-11-24(22)3)21-14-19(16-7-5-4-6-8-16)18-10-9-17(23)13-20(18)21/h4-10,13,19,21H,11-12,14-15H2,1-3H3/t19-,21+/m0/s1
  • Key:BYPMJBXPNZMNQD-PZJWPPBQSA-N

Zicronapine (/zaɪˈkrɒnəpiːn/ zye-KRON-ə-peen, previously known as Lu 31-130) is an atypical antipsychotic medication[1] formerly under development by H. Lundbeck A/S. In phase II studies zicronapine showed statistically significant separation from placebo and convincing efficacy and safety data when compared to olanzapine.[2]

Zicronapine exhibits monoaminergic activity and has a multi-receptorial profile. In vitro and in vivo it has shown potent antagonistic effects at dopamine D1, D2 and serotonin 5HT2A receptors.[3]

In 2014 Lundbeck removed zicronapine from its development portfolio in favor of pursuing the more promising antipsychotic Lu AF35700 (a prodrug of Lu AF356152).[4]

References

  1. ^ Citrome L (November 2013). "A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach". CNS Drugs. 27 (11): 879–911. doi:10.1007/s40263-013-0105-7. PMID 24062193. S2CID 23867019.
  2. ^ "The clinical phase III programme commenced on zicronapine". January 20, 2011. Archived from the original on 2 February 2017. Retrieved 6 February 2014.
  3. ^ "Zicronapine shows significant positive data in clinical phase II in the treatment of patients with schizophrenia - planning for continued clinical work". December 18, 2009. Archived from the original on 8 October 2016. Retrieved 6 February 2014.
  4. ^ "Performance in 2014 positions Lundbeck well for 2015 and beyond" (PDF). February 5, 2015. Archived from the original (PDF) on 18 June 2015. Retrieved 18 June 2015.

External links

  • Media related to Zicronapine at Wikimedia Commons
  • v
  • t
  • e
Antipsychotics (N05A)
Typical
DisputedAtypicalOthers
  • v
  • t
  • e
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists
  • See also: Receptor/signaling modulators
  • Adrenergics
  • Serotonergics
  • Monoamine reuptake inhibitors
  • Monoamine releasing agents
  • Monoamine metabolism modulators
  • Monoamine neurotoxins
  • v
  • t
  • e
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT3–7
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
  • See also: Receptor/signaling modulators
  • Adrenergics
  • Dopaminergics
  • Melatonergics
  • Monoamine reuptake inhibitors and releasing agents
  • Monoamine metabolism modulators
  • Monoamine neurotoxins


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e
Stub icon

This psychiatry-related article is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e